Gynecologic Cancer
Conference Coverage
PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer
BARCELONA – Benefit was particularly pronounced in patients with a tumor BRCA mutation and those with homologous recombination deficiency (HRD)–...
Conference Coverage
BAROCCO study: Cediranib-olaparib combination shows promise in PROC
BARCELONA –
Conference Coverage
Closure of women’s health clinics may negatively impact cervical cancer outcomes
Mortality risk among women with cervical cancer was 36% higher in states that had a decreased number of women’s clinics.
News
FDA approves pembrolizumab/lenvatinib combo for advanced endometrial carcinoma
The approval is based on positive results from the KEYNOTE-146 trial.
From the Journals
Nivolumab may be beneficial for recurrent or metastatic cervical cancer
Study results underscore the growing role of immune checkpoint inhibitors in virus-associated cancers.
From the Journals
Perceived discrimination linked to delay in ovarian cancer diagnosis for black women
In a case-control analysis, researchers found that every 1-unit rise in the frequency of everyday discrimination was associated with a higher...
Opinion
Ovarian cancer and perineal talc exposure: An epidemiologic dilemma
Recall bias and lack of an established biologic mechanism are a few reasons perineal talc exposure isn’t considered a definitive cause of ovarian...
From the Journals
Pretreatment CT data may help predict immunotherapy benefit in ovarian cancer
Fewer sites of disease and lower intratumor heterogeneity on contrast-enhanced CT may indicate a higher likelihood of durable response to immune...
From the Journals
Benefit of chemo + RT for high-risk endometrial cancer increases with time
With longer follow-up, analyses showed emergence of a significant overall survival benefit of adjuvant chemoradiotherapy over radiotherapy alone,...
Conference Coverage
Ovarian cancer diagnosed and treated earlier under ACA
CHICAGO – Ovarian cancer is more often diagnosed at an earlier stage and treated within 30 days under the ACA, vs. pre-ACA.
From the Journals
Vaginal microbiota composition linked to ovarian cancer risk
In a case-control analysis, women under 50 years of age with ovarian cancer were more likely to have a community type O microbiota relative to age...